IPM Take
Alzheimer’s medicine is entering the blood-test era. That is progress, but it is not magic.
Using pTau217 to confirm Alzheimer’s pathology before enrolment is a smarter way to build a pivotal trial. It reduces diagnostic noise and moves the field closer to targeted evidence. But a cleaner trial population does not automatically create a better treatment.
The real test for buntanetap is still brutal and simple: does it help people think, function and remain independent for longer?
Executive Summary
Annovis Bio announced full enrolment in its pivotal Phase III study of buntanetap in early Alzheimer’s disease. The trial enrolled 850 participants across 83 clinical sites in the United States, exceeding the company’s original enrolment target.
The randomised, double-blind, placebo-controlled study includes people with early Alzheimer’s disease, defined by MMSE scores of 20 to 28, and requires confirmation of Alzheimer’s pathology using pTau217. Participants receive daily oral buntanetap 30 mg or placebo.
The company describes the study as having two components: a six-month symptomatic readout expected in the first quarter of 2027 and an 18-month disease-modifying readout expected in the first quarter of 2028. Primary endpoints include ADAS-Cog13 and ADCS-iADL.
This is an enrolment milestone, not an efficacy result. No clinical outcome data have been reported from the pivotal trial.
Why it matters
- Patients / advocates: Blood-based selection may make Alzheimer’s trials more precise, but patients need evidence of preserved memory, function and independence, not only cleaner enrolment.
- Clinicians: pTau217-confirmed inclusion reflects a shift away from purely clinical diagnosis toward biologically anchored trials.
- Researchers / academia: The design shows how Alzheimer’s trials are becoming more biomarker-gated, but endpoint interpretation will remain decisive.
- Regulators: A trial can be biologically enriched and still fail clinically. The burden remains on patient-relevant outcomes.
Alzheimer’s trials have spent years fighting a basic problem: not everyone enrolled in an Alzheimer’s trial necessarily has the same Alzheimer’s biology.
That matters. A drug can look weaker than it is if the trial population is noisy. A signal can look stronger than it is if biomarkers are over-read. Either way, patients pay for uncertainty with time.
Annovis’s pivotal buntanetap trial is worth watching because it uses pTau217 confirmation to sharpen the evidence base before the treatment question is answered. That does not prove the drug works. It does make the trial harder to dismiss as biologically vague.
The politics of Alzheimer’s are now moving into a new phase.
The field has learned that biomarkers can identify disease biology earlier and more precisely. But the access system is not yet ready for what that means. Blood tests may help decide who enters trials, who receives treatment, who gets referred to specialists and who is told to wait.
That creates opportunity. It also creates power.
A blood-gated trial can make evidence cleaner. A blood-gated health system could also become another bottleneck if testing access, interpretation and referral remain uneven. The same tool that improves science can widen inequity if it is not built into routine care.
Buntanetap still has to prove itself. The trial has not produced efficacy data. But the design tells us something important already: Alzheimer’s evidence is moving toward biological precision. Now the system has to prove it can deliver precision without creating a new access divide.
